FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML

FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML

Submitted by admin on May 4, 2020 - 10:36am
Source: 
Pharmaceutical Business Review
News Tags: 
Bristol-Meyers Squibb
FDA
CC-486
AML
acute myeloid leukemia
Headline: 
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML
snippet: 

Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486 for the maintenance treatment of adults in remission with acute myeloid leukemia (AML)

Do Not Allow Advertisers to Use My Personal information